Prompted by an FDA letter requesting additional clinical testing, the firm expects to shut down its development of a babesia blood-donor screening assay.
US civil surgeons screening immigrants for TB will need to perform an IGRA from Qiagen or Oxford Immunotec, instead of the decades-old tuberculin skin test.
Leading the gainers in the 360 Index was GenMark, whose stock price was up 30 percent last month. Invitae led the decliners as its share price fell 24 percent.
Luminex was bullish about its molecular diagnostics business, Natera outlined its work with pharmaceutical firms, and Oxford discussed its plans in TB and tick-borne diseases.